Identifizierung von Biomarkern für die Prognose der Gemcitabin-Therapie beim Pankreaskarzinom: RNA-, DNA- und Immunhistochemische- Analysen

Identification of biomarkers for the prognosis in gemcitabine treated pancreatic cancer: RNA-, DNA- and immunhistochemical- analysis

by Christian Zimmer
Doctoral thesis
Date of Examination:2015-02-11
Date of issue:2015-02-06
Advisor:Prof. Dr. Jürgen Brockmöller
Referee:Prof. Dr. Volker Ellenrieder
Referee:Prof. Dr. Margarete Schön
Persistent Address: http://dx.doi.org/10.53846/goediss-4903

 

 

Files in this item

Name:Dissertation_CZimmer_SUB.pdf
Size:2.31Mb
Format:PDF
Description:Medizinsche Dissertation

The following license files are associated with this item:

Abstract

English

One aim of this study was to investigate the associations of genetic polymorphisms in the genes involved in gemcitabine pathways and the cinical outcome of patients with pancreatic ductal adenocarcinoma. A nucleoitide polymorphism in ENT1 (SLC29A1) gene, a transmembrane transporter of gemcitabine, had an influence on overall survival. Based on immunhistochemical analysis it could be shown, that patients with a high ENT1 protein expression benefits from a gemcitabin therapy. 
Keywords: pankreatic cancer; gemcitabin treatment; ent1; genetic polymorphisms; nucleoside transporter
Schlagwörter: Gemcitabin; Pankreaskarzinom; ENT1; genetische Polymorphismen; Nukleosid Transporter
 
Statistik